---
title: "Repatha (evolocumab) in cardiovascular event risk reduction: Safety questions"
description: "Safety questions on Repatha (evolocumab) in cardiovascular event risk reduction, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Safety evidence and Side effects. Questions: Does Repatha affect memory or cognitive function (EBBINGHAUS)? What are the most common side effects of Repatha in cardiovascular outcomes trials? Does Repatha increase the risk of diabetes? What did VESALIUS-CV show about Repatha's long-term safety? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Repatha (evolocumab) in cardiovascular event risk reduction: Safety questions

Manufacturer: Amgen Inc.  
Prescribing information: [Repatha](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf)

Safety questions that apply to every indication of Repatha are on [Repatha (evolocumab), all indications: Safety](https://www.evicenter.com/medical-information/repatha/safety).

## Safety evidence

<a id="repatha-cognitive-function"></a>

### Does Repatha affect memory or cognitive function (EBBINGHAUS)?

> “In EBBINGHAUS (NCT02207634), a substudy of 1,974 patients enrolled in the FOURIER trial, 
> REPATHA was non-inferior to placebo on selected cognitive function domains as assessed with the use 
> of neuropsychological function tests over a median follow-up of 19 months.”

Source: [REPATHA: Prescribing information, page 15, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=15)

Note: In FOURIER, patients with established cardiovascular disease on statin therapy received REPATHA 140 mg every 2 weeks or 420 mg once monthly, or placebo.

## Side effects

<a id="repatha-cv-trial-side-effects"></a>

### What are the most common side effects of Repatha in cardiovascular outcomes trials?

> “Trial 1 (FOURIER) 
> In a double-blind, randomized, placebo-controlled CV outcomes trial in patients with established 
> atherosclerotic cardiovascular disease (ASCVD), 27,525 patients received at least one dose of REPATHA 
> or placebo [see Clinical Studies (14)]. The mean age was 62.5 years (range: 40 to 86 years), 45% were 65 
> years or older, 9% were 75 years or older, 25% female, 85% White, 10% Asian, and 2% Black or African 
> American; 8% identified as Hispanic or Latino ethnicity. Patients were exposed to REPATHA or placebo 
> for a median of 24.8 months; 91% of patients were exposed for ≥ 12 months, 54% were exposed for ≥ 24 
> months and 5% were exposed for ≥ 36 months. 
>
> The safety profile of REPATHA in this trial was generally consistent with the safety profile described 
> above in the 12- and 52-week controlled trials involving patients with hypercholesterolemia. Common 
> adverse reactions (> 5% of patients treated with REPATHA and occurring more frequently than placebo) 
> included diabetes mellitus (8.8% REPATHA, 8.2% placebo), nasopharyngitis (7.8% REPATHA, 7.4% 
> placebo), and upper respiratory tract infection (5.1% REPATHA, 4.8% placebo).”

Source: [REPATHA: Prescribing information, page 6, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=6)

> “The safety profile of REPATHA in this trial was consistent with the known safety profile of REPATHA.”

Source: [REPATHA: Prescribing information, page 7, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=7)

Note: The second passage concerns Trial 2 (VESALIUS-CV), in patients at high cardiovascular risk without a prior myocardial infarction or stroke.

<a id="repatha-diabetes-risk"></a>

### Does Repatha increase the risk of diabetes?

> “Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes 
> mellitus during the trial was 8.1% in patients treated with REPATHA compared with 7.7% in patients that 
> received placebo.”

Source: [REPATHA: Prescribing information, page 6, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=6)

Note: These figures are from FOURIER, a placebo-controlled trial in patients with established atherosclerotic cardiovascular disease with a median exposure of 24.8 months.

<a id="repatha-long-term-side-effects"></a>

### What did VESALIUS-CV show about Repatha's long-term safety?

> “Trial 2 (VESALIUS-CV) 
> In another double-blind, randomized, placebo-controlled cardiovascular outcomes trial in patients at high 
> CV risk without a prior myocardial infarction or stroke, including those with ASCVD or diabetes mellitus 
> with additional risk factors for CV disease, 12,196 patients received at least one dose of REPATHA 
> (6,102) or placebo (6,094) [see Clinical Studies (14)].”

Source: [REPATHA: Prescribing information, page 6, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=6)

> “A total of 6,102 patients were exposed to 
> REPATHA for a median of 53 months; 84% of patients were exposed for ≥ 36 months, 62% were 
> exposed for ≥ 48 months, and 22% were exposed for ≥ 60 months.”

Source: [REPATHA: Prescribing information, page 7, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=7)

> “The safety profile of REPATHA in this trial was consistent with the known safety profile of REPATHA.”

Source: [REPATHA: Prescribing information, page 7, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=7)

## Related pages
- [Medical information: Repatha (evolocumab): Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction)
- [Indication](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/clinical-trials)
- [Dosing and administration](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/guidelines)
